ORLANDO, Fla.—The use of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is feasible and efficacious for the prevention of graft-versus-host disease (GVHD) in a series of patients ...

In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and ...

We used everolimus (RAD001) to inhibit mTOR, alone or in combination with anti-EGFR drugs gefitinib or cetuximab, on human cancer cell lines sensitive and resistant to EGFR inhibitors, both in ...

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain ...

In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others ...

To provide further rationale for using the mTOR inhibitor everolimus in MCL, we evaluated mTOR activity in three mantle cell lines Jeko, Mino and Granta by measuring the phosphorylation profile of ...

April 27, 2010 (Chicago, Illinois) — In the 1-year planned interim analysis of the CeMyLungs study, both mycophenolate sodium (MPS) and the mTOR inhibitor everolimus were associated with ...

WOODCLIFF LAKE, N.J., Nov. 7, 2020 /PRNewswire/ -- Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of tw ...

mTOR inhibitors are PI3K-related kinases that ... Rapamycin and analogs temsirolimus (Torisel), everolimus (Afinitor), and the investigational agent ridaforolimus (Merck and Ariad Pharmaceuticals ...

The data also indicate that the wound healing issues observed in early studies with high exposure to mTOR inhibitors can be prevented with reduced exposure to both everolimus and tacrolimus in ...